Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 1/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 4/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.41 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8050443 | 0.88 | GAK (0.50) | FADS1RIPK2KDRHTR2AGAK | |
| SCHEMBL8045380 | 0.85 | POLB (0.56) | FADS1KDRHTR2APOLBSLC2A1 | |
| SCHEMBL8040347 | 0.84 | HTR2A (0.44) | HTR2AMAPTSMN1; SMN2NPSR1POLB | |
| SCHEMBL12810880 | 0.82 | HTR2A (0.39) | HTR2AMAPTSMN1; SMN2NPSR1KMT2A | |
| SCHEMBL8050446 | 0.82 | HTR2A (0.35) | HTR2AMAPTSMN1; SMN2NPSR1KMT2A | |
| SCHEMBL8043495 | 0.80 | USP2 (0.49) | RIPK2GAKCOQ8ANLKMAPT | |
| SCHEMBL8042888 | 0.76 | RIPK2 (0.41) | RIPK2HTR2AGAKCOQ8ANLK | |
| SCHEMBL13130694 | 0.73 | HTR2A (0.38) | HTR2AMAPTSMN1; SMN2NPSR1KMT2A | |
| SCHEMBL8043533 | 0.72 | HTR2A (0.47) | HTR2AMAPTSMN1; SMN2NPSR1POLB | |
| SCHEMBL8045371 | 0.72 | MTNR1A (0.49) | HTR2AKMT2AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583524-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-21 | — | — | US | disclosed |
| US-20200121667-A1 | Inhibitors Of The Interaction Between MDM2 And P53 | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-23 | — | — | US | disclosed |
| US-20170112818-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-27 | — | — | US | disclosed |
| US-20170112818-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-27 | — | — | US | disclosed |
| US-9573933-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-21 | — | — | US | disclosed |
| US-9573933-B2 | Inhibitors of the interaction between MDM2 and P53 | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-21 | — | — | US | disclosed |
| EP-2203440-B1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-23 | — | — | EP | disclosed |
| US-20100240637-A1 | Inhibitors of the Interaction Between MDM2 and P53 | JANSSEN PHARMACEUTICAL NV (BE) | 2010-09-23 | — | — | US | disclosed |
| US-20100240637-A1 | Inhibitors of the Interaction Between MDM2 and P53 | JANSSEN PHARMACEUTICAL NV (BE) | 2010-09-23 | — | — | US | disclosed |
| WO-2009037308-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240637-A1 | Inhibitors of the Interaction Between MDM2 and P53 | TP53, MDM2, TP53BP1 | FADS1 3008/4885RIPK2 741/4885KDR 2861/4885 |
| US-20170112818-A1 | INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53 | TP53, MDM2, TP53BP1 | FADS1 3008/4885RIPK2 741/4885KDR 2861/4885 |
| US-11583524-B2 | Inhibitors of the interaction between MDM2 and P53 | TP53, MDM2, TP53BP1 | FADS1 3008/4885RIPK2 741/4885KDR 2861/4885 |
| US-20200121667-A1 | Inhibitors Of The Interaction Between MDM2 And P53 | TP53, MDM2, TP53BP1 | FADS1 2923/4885RIPK2 829/4885KDR 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.